Chronic Kidney Disease: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Chronic Kidney Disease: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

  • 175 Pages | 17-Jan-19 | Format:PDF | Last Updated: 17-Jan-19
  • GervanoRA’s pipeline analysis and opportunity assessment report “Chronic Kidney Disease: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018” analyzed and assessed Chronic Kidney Disease pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Chronic Kidney Disease industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.
    Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Unmet needs and Opportunities
    • Epidemiology and Epidemiology forecast 2018 – 2023
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Patent Analysis of Pipeline Molecules
    • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
    • Clinical Trials Summary
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Emerging Company Profiles with Opportunity Assessments
    • Pipeline Drug Descriptions along with Development milestones (Past and Future)
    Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

  • TABLE OF CONTENTS
    1. INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2. EXECUTIVE SUMMARY
    2.1. REPORT MAJOR FINDINGS
    2.2. KEY EVENTS IN CHRONIC KIDNEY DISEASE COMPETITIVE SPACE
    3. DISEASE OVERVIEW
    3.1. DISEASE DEFINITION & SYMPTOMS
    3.1.1. CLINICAL MANIFESTATIONS
    3.1.2. PATHOGENESIS
    3.2. DISEASE CAUSE AND CLASSIFICATION
    3.3. DISEASE DIAGNOSIS
    3.4. TREATMENT ALGORITHM AND GUIDELINES
    3.5. EPIDEMIOLOGY AND DISEASE BURDEN
    3.6. EPIDEMIOLOGY FORECAST
    3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
    4. MARKET DYNAMICS
    4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
    4.2. PRICING AND REIMBURSEMENT
    4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    4.4. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    5. PIPELINE ANALYSIS
    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    5.1.1. PRE-REGISTRATION MOLECULES
    5.1.2. PHASE 3 MOLECULES
    5.1.3. PHASE 2 MOLECULES
    5.1.4. PHASE 1 MOLECULES
    5.1.5. PRECLINICAL MOLECULES
    5.1.6. EARLY R&D MOLECULES
    5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    5.2.1. UNMET NEEDS AND OPPORTUNITIES
    5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    5.3.1. UNMET NEEDS AND OPPORTUNITIES
    5.4. PIPELINE ANALYSIS BY DRUG CLASS
    5.4.1. UNMET NEEDS AND OPPORTUNITIES
    5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    5.5.1. UNMET NEEDS AND OPPORTUNITIES
    6. ESTIMATED APPROVAL TIMELINE
    6.1.1. METHODOLOGY
    6.1.2. ESTIMATED APPROVAL TIMELINES US & EX-US
    7. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    7.1. COMPANIES
    7.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
    7.1.1.1. ASTRAZENECA PLC
    7.1.1.2. ELI LILLY AND COMPANY
    7.1.1.3. OPKO HEALTH INC
    7.1.1.4. GILEAD SCIENCES, INC
    7.1.1.5. ASTELLAS PHARMA
    7.2. EMERGING COMPANIES
    7.2.1. ALGOMEDIX TRP THERAPEUTICS
    7.2.2. ALLENA PHARMACEUTICALS
    7.2.3. NOVADIOL INC
    7.2.4. PALLADIO BIOSCIENCES
    7.2.5. PROLONG PHARMACEUTICALS LLC
    7.2.6. PROTEON THERAPEUTICS, INC
    7.2.7. REGENMEDTX LLC
    7.2.8. RESVERLOGIX
    7.2.9. SPHAERA PHARMA
    7.2.10. THRASOS THERAPEUTICS
    7.2.11. TRICIDA INC
    7.2.12. VIDASYM
    7.2.13. ANGION BIOMEDICA CORP
    7.2.14. KIDNEYCURE LTD
    7.2.15. PROMETIC LIFE SCIENCES INC
    7.2.16. CORVIDIA THERAPEUTICS
    7.2.17. EMBER THERAPEUTICS
    7.2.18. INOSITEC AG
    7.2.19. KBP BIOSCIENCES CO LTD
    7.2.20. MISSION THERAPEUTICS
    8. ABBREVIATIONS

    LIST OF TABLES
    TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
    TABLE 02: CLASSIFICATION OF CKD USING GFR AND ACR CATEGORIES
    TABLE 03: RECOMMENDATIONS PROVIDED BY AMERICAN COLLEGE OF PHYSICIANS
    TABLE 04: CKD EPIDEMIOLOGY (2017), FORECAST (2018-2023) IN MILLIONS
    TABLE 05: CKD FINANCING ACTIVITY IN $M
    TABLE 06: MAJOR COLLABORATIVE AGREEMENTS IN CKD THERAPEUTIC AREA
    TABLE 07: MAJOR LICENSING AGREEMENTS IN CKD THERAPEUTIC AREA
    TABLE 08: MAJOR MERGERS AND PARTNERSHIPS IN CKD THERAPEUTIC AREA
    TABLE 09: PHASE 3 MOLECULES IN THE CKD DRUG PIPELINE
    TABLE 10: PHASE 2 MOLECULES IN THE CKD DRUG PIPELINE
    TABLE 11: PHASE 1 MOLECULES IN THE CKD DRUG PIPELINE
    TABLE 12: PRECLINICAL MOLECULES IN THE CKD DRUG PIPELINE
    TABLE 13: CKD DRUG PIPELINE MOLECULES BY ORAL AS ROUTE OF ADMINISTRATION
    TABLE 14: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
    TABLE 15: ASTRAZENECA PRODUCT PORTFOLIO
    TABLE 16: DRUGS APPROVALS BY ASTRAZENECA
    TABLE 17: R&D ACTIVITIES OF ASTRAZENECA
    TABLE 18: CONFERENCES/EVENTS ATTENDED BY ASTRAZENECA
    TABLE 19: RECENT DEVELOPMENTS MADE BY ASTRAZENECA
    TABLE 20: ELI LILLY & COMPANY PRODUCT PORTFOLIO
    TABLE 21: OTHER PHASE 2 AND PHASE 1 PROGRAM
    TABLE 22: OTHER PHASE 2 AND PHASE 1 PROGRAM
    TABLE 23: OTHER PHASE 2 AND PHASE 1 PROGRAM
    TABLE 24: OTHER PHASE 2 AND PHASE 1 PROGRAM
    TABLE 25: R&D ACTIVITIES OF ELI LILLY & COMPANY
    TABLE 26: CONFERENCES/EVENTS ATTENDED BY ELI LILLY & COMPANY
    TABLE 27: RECENT DEVELOPMENTS MADE BY ELI LILLY & COMPANY
    TABLE 28: R&D ACTIVITIES OF OPKO HEALTH
    TABLE 29: CONFERENCES/EVENTS ATTENDED BY OPKO HEALTH
    TABLE 30: RECENT DEVELOPMENTS MADE BY OPKO HEALTH
    TABLE 31: GILEAD SCIENCES PRODUCT PORTFOLIO
    TABLE 32: R&D ACTIVITIES OF GILEAD SCIENCES
    TABLE 33: REGULATORY PROGRESS BY GILEAD SCIENCES
    TABLE 34: CONFERENCES/EVENTS ATTENDED BY GILEAD SCIENCES
    TABLE 35: RECENT DEVELOPMENTS MADE BY GILEAD SCIENCES
    TABLE 36: ASTELLAS PHARMA PRODUCT PORTFOLIO
    TABLE 37: APPROVALS AND LANCHES BY ASTELLAS PHARMA
    TABLE 38: R&D ACTIVITIES OF ASTELLAS PHARMA
    TABLE 39: RECENT DEVELOPMENTS MADE BY ASTELLAS PHARMA
    TABLE 40: EMERGING OPPORTUNITIES IN CKD THERAPEUTIC AREA
    TABLE 41: EVENTS/CONFERENCES ATTENDED BY ALGOMEDIX
    TABLE 42: FUTURE MILESTONE EVENTS OF ALLENA PHARMACEUTICALS
    TABLE 43: R&D ACTIVITIES BY ALLENA PHARMACEUTICALS
    TABLE 44: EVENTS/CONFERENCES ATTENDED BY ALLENA PHARMACEUTICALS
    TABLE 45: R&D ACTIVITIES BY PALLADIO BIOSCIENCES
    TABLE 46: RECENT DEVELOPMENTS BY PALLADIO BIOSCIENCES
    TABLE 47: R&D ACTIVITIES BY PROLONG PHARMACEUTICALS
    TABLE 48: EVENTS/CONFERENCES ATTENDED BY PROLONG PHARMACEUTICALS
    TABLE 49: EVENTS AND CONFERENCES ATTENDED BY PROTEON THERAPEUTICS
    TABLE 50: RECENT DEVELOPMENTS BY PROTEON THERAPEUTICS
    TABLE 51: FUTURE MILESTONE EVENTS OF RESVERLOGIX
    TABLE 52: R&D ACTIVITIES BY RESVERLOGIX
    TABLE 53: EVENTS/CONFERENCES ATTENDED BY RESVERLOGIX
    TABLE 54: RECENT DEVELOPMENTS BY RESVERLOGIX
    TABLE 55: RECENT DEVELOPMENTS BY SPHAERA PHARMA
    TABLE 56: FUTURE MILESTONE EVENTS OF TRICIDA INC
    TABLE 57: R&D ACTIVITIES BY TRICIDA
    TABLE 58: EVENTS/CONFERENCES ATTENDED BY TRICIDA
    TABLE 59: R&D ACTIVITIES BY ANGION BIOMEDICA CORP
    TABLE 60: EVENTS/CONFERENCES ATTENDED BY ANGION BIOMEDICA CORP
    TABLE 61: RECENT DEVELOPMENTS BY ANGION BIOMEDICA CORP
    TABLE 62: FUTURE MILESTONE EVENTS OF PROMETIC LIFE SCIENCES
    TABLE 63: R&D ACTIVITIES BY PROMETIC LIFE SCIENCES
    TABLE 64: EVENTS/CONFERENCES ATTENDED BY PROMETIC LIFE SCIENCES
    TABLE 65: RECENT DEVELOPMENTS BY PROMETIC LIFE SCIENCES
    TABLE 66: RECENT DEVELOPMENTS BY CORVIDIA THERAPEUTICS
    TABLE 67: AGREEMENTS AND ACQUISITIONS MADE BY EMBER THERAPEUTICS
    TABLE 68: RECENT DEVELOPMENTS BY INOSITEC
    TABLE 69: R&D ACTIVITIES BY KBP BIOSCIENCES
    TABLE 70: EVENTS/CONFERENCES ATTENDED BY KBP BIOSCIENCES
    TABLE 71: RECENT DEVELOPMENTS BY MISSION THERAPEUTICS
    TABLE 72: EVENTS/CONFERENCES ATTENDED BY MISSION THERAPEUTICS

    LIST OF FIGURES
    FIGURE 01: KEY PIPELINE EVENTS, 2018-2029
    FIGURE 02: CKD EPIDEMIOLOGY (2017), FORECAST (2018-2023) IN MILLIONS
    FIGURE 03: OVERALL DEALS ACTIVITY IN CKD THERAPEUTIC AREA
    FIGURE 04: OVERALL DEAL FINANCING ACTIVITY V/S DEAL TYPE
    FIGURE 05: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
    FIGURE 06: CKD DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
    FIGURE 07: CKD DRUG PIPELINE ANALYSIS BY GEOGRAPHY
    FIGURE 08: CKD DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
    FIGURE 09: CKD DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINSTRATION
    FIGURE 10: FINANCIAL INFORMATION OF ASTRAZENECA
    FIGURE 11: SWOT ANALYSIS OF ASTRAZENECA
    FIGURE 12: FINANCIAL INFORMATION OF ELI LILLY & COMPANY
    FIGURE 13: SWOT ANALYSIS OF ELI LILLY & COMPANY
    FIGURE 14: FINANCIAL INFORMATION OF OPKO HEALTH INC (REVENUES IN $ THOUSANDS AND R&D IN $M)
    FIGURE 15: SWOT ANALYSIS OF OPKO HEALTH
    FIGURE 16: FINANCIAL INFORMATION OF GILEAD SCIENCES
    FIGURE 17: SWOT ANALYSIS OF GILEAD SCIENCES
    FIGURE 18: FINANCIAL INFORMATION OF ASTELLAS PHARMA
    FIGURE 19: SWOT ANALYSIS OF ASTELLAS PHARMA

Pricing

Individual Pricing $2500

Corporate Pricing $2500

Enterprise Pricing $2500

(We are offering all the above license types for a single price!!)